PCDPrivate Comps Data

Company record · updated August 5, 2026

Tessera Therapeutics Ser C' Cvt Pfd: 7 valuation observations from SEC filings

Every row below names the filing it came from. Coverage for this company runs September 30, 2025 to March 31, 2026.

7observations
7source filings
7verified rows
2026-03-31most recent as-of date

Source rails for this company: N-PORT fund mark (7).

Reported by 3 filers: T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio, T. Rowe Price New Horizons Fund, Inc..

As ofMeasureValueReported byTier What the filing saysAccession
2026-03-31 price per share 5.18 USD T. Rowe Price Health Sciences Portfolio VERIFIED valUSD 157674.02 / balance 30439.0 [series c] 000109926326006593
2026-03-31 price per share 5.18 USD T. Rowe Price Health Sciences Fund, Inc. VERIFIED valUSD 3492221.32 / balance 674174.0 [series c] 000109926326006598
2025-12-31 price per share 5.18 USD T. Rowe Price Health Sciences Portfolio VERIFIED valUSD 157674.02 / balance 30439.0 [series c] 000109926326002544
2025-12-31 price per share 5.18 USD T. Rowe Price Health Sciences Fund, Inc. VERIFIED valUSD 3492221.32 / balance 674174.0 [series c] 000109926326002549
2025-12-31 price per share 5.18 USD T. Rowe Price New Horizons Fund, Inc. VERIFIED valUSD 4280808.98 / balance 826411.0 [series c] 000109926326002508
2025-09-30 price per share 5.18 USD T. Rowe Price Health Sciences Fund, Inc. VERIFIED valUSD 3492221.32 / balance 674174.0 [series c] 000109926325003642
2025-09-30 price per share 5.18 USD T. Rowe Price Health Sciences Portfolio VERIFIED valUSD 157674.02 / balance 30439.0 [series c] 000109926325003637

Reading these figures

A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.